ASSENT 1-TIMI 10C

ASSENT I-(TIMI 10C) compared the safety of several doses of TNK-tPA with rtPA in 3,235 patients with ST elevation myocardial infarction.

MAIN RESULTS:
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial.

Am Heart J. 1999 May;137(5):786-91.

PRESENTATIONS

TIMI 10C Slides

OTHER PUBLICATIONS

Determination of a weight-adjusted dose of TNK-tissue plasminogen activator. Am Heart J. 2001 Jan;141(1):33-40.